Abstract
AbstractDiscovered 60 years ago, lipoprotein (a) was very quickly recognized as an independent cardiovascular risk factor when its genetically determined concentration was high. Lp(a) is a lipoprotein containing apolipoprotein B100 like LDL but distinguished by the presence of an apolipoprotein (a) molecule. This apo(a) exhibits a very great structural heterogeneity as a function of the number of copies of the “kringle IV2” motif, making it possible to distinguish between small isoforms and large isoforms. The plasma concentration of Lp(a) is inversely proportional to the size of the apo(a) present in the Lp(a). The atherogenic properties of Lp(a) are linked to the LDL fraction, its thrombogenic properties are due to the anti- fibrinolytic action of apo(a) due to its partial homology with plasminogen. More recently a role in vascular calcification has also been demonstrated. During the 2000s, interest in Lp(a) declined considerably. Lp(a) is now back in the spotlight because its dosage makes it possible to improve the identification and management of subjects at high cardiovascular risk and because new therapies to reduce the synthesis of apo(a) look promising.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
